EPHA5
EPHA5 (Ephrin type-A receptor 5) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.
Overview
Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells. The signalling pathway downstream of the receptor is referred to as forward signalling while the signalling pathway downstream of the ephrin ligand is referred to as reverse signalling. Among GPI-anchored ephrin-A ligands, EFNA5 most probably constitutes the cognate/functional ligand for EPHA5.
Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.39, clinical 0.93).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · EPHA5 (Ephrin type-A receptor 5) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.
- 1 · What it is
EPHA5 (Ephrin type-A receptor 5) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.
- 2 · What goes wrong in cancer
Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells.
- 3 · How drugs use it
No product in this corpus aims at EPHA5 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
External identifiers
Sources: HGNC HGNC:3389 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P54756 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000145242 (association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: thyroid cancer 0.57, neuroendocrine neoplasm 0.54 (GraphQL API, CC0))
Biology
Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signalling into neighboring cells. The signalling pathway downstream of the receptor is referred to as forward signalling while the signalling pathway downstream of the ephrin ligand is referred to as reverse signalling. Among GPI-anchored ephrin-A ligands, EFNA5 most probably constitutes the cognate/functional ligand for EPHA5. Functions as an axon guidance molecule during development and may be involved in the development of the retinotectal, entorhino-hippocampal and hippocamposeptal pathways. Together with EFNA5 plays also a role in synaptic plasticity in adult brain through regulation of synaptogenesis. In addition to its function in the nervous system, the interaction of EPHA5 with EFNA5 mediates communication between pancreatic islet cells to regulate glucose-stimulated insulin secretion. Location: Cell membrane; Cell projection, axon; Cell projection, dendrite (UniProt). Locus 4q13.1-q13.2 (HGNC).
- Thyroid cancer: Open Targets association 0.57 with thyroid cancer (MONDO_0002108)
- Neuroendocrine tumours: Open Targets association 0.54 with neuroendocrine neoplasm (MONDO_0019496)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.93. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"EPHA5" OR ABSTRACT:"EPHA5" OR TITLE:"EPH receptor A5" OR ABSTRACT:"EPH receptor A5" OR TITLE:"Ephrin type-A receptor 5" OR ABSTRACT:"Ephrin type-A receptor 5" OR TITLE:"Hek7" OR ABSTRACT:"Hek7" OR TITLE:"TYRO4" OR ABSTRACT:"TYRO4" OR TITLE:"CEK7" OR ABSTRACT:"CEK7") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EPHA5, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetEPHA1
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
- TargetEPHA10
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
- TargetEPHA4
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
- TargetEPHA6
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
- TargetEPHA8
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
- TargetEPHB1
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
- TargetEPHB3
Shares Thyroid cancer, Neuroendocrine tumours, Open Targets Platform.
- TargetFOXE1
Shares Thyroid cancer, Open Targets Platform.